| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 146, Issue 7 2245-2248, Copyright © 1991 by American Association of Immunologists
ARTICLES |
VA Lennon, EH Lambert, KR Leiby, TB Okarma and S Talib
Department of Immunology, Mayo Clinic, Rochester, MN 55905.
A synthetic gene encoding the 210 N-terminal residues of the alpha- subunit of the nicotinic acetylcholine receptor (AChR) of human skeletal muscle was cloned into an inducible expression plasmid to produce a fusion protein in high yield in Escherichia coli. Like native human AChR, the recombinant human alpha 1-210 protein induced AChR- binding, AChR-modulating, and AChR-blocking autoantibodies in rats when injected once intradermally as an emulsion in CFA, with Bordetella pertussis vaccine as supplementary adjuvant. The minimum dose of recombinant protein required to induce biochemical signs of experimental autoimmune myasthenia gravis (EAMG) with 100% incidence was 2.2 micrograms. With 6.6 to 22 micrograms, serum levels of autoantibodies were persistent, and clinically apparent EAMG lasted more than a month. Clinical, electrophysiological, and biochemical indices of EAMG induced by doses of 66 micrograms or more were more uniformly severe and persistent, with 33% fatality. Rats receiving a control extract of E. coli containing plasmid without the alpha 1-210 codon insert, with adjuvants, did not develop autoantibodies or signs of EAMG. This highly reproducible new model of EAMG induced by a recombinant human autoantigen should be valuable for testing Ag- specific immunotherapeutic strategies that might be applicable to treating acquired myasthenia gravis in humans.
This article has been cited by other articles:
|
|
 |
|
  R. Aricha, T. Feferman, S. Fuchs, and M. C. Souroujon Ex Vivo Generated Regulatory T Cells Modulate Experimental Autoimmune Myasthenia Gravis J. Immunol., February 15, 2008; 180(4): 2132 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhou, B. Gong, F. Lin, R. P. Rother, M. E. Medof, and H. J. Kaminski Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis J. Immunol., December 15, 2007; 179(12): 8562 - 8567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yang, B. Wu, E. Tuzun, S. S. Saini, J. Li, W. Allman, S. Higgs, T. L. Xiao, and P. Christadoss A New Mouse Model of Autoimmune Ocular Myasthenia Gravis Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 5101 - 5111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishino, S. K. Ashiku, O. N. Kocher, R. L. Thurer, P. M. Boiselle, and H. Hatabu The thymus: a comprehensive review. RadioGraphics, March 1, 2006; 26(2): 335 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Feferman, P. K. Maiti, S. Berrih-Aknin, J. Bismuth, J. Bidault, S. Fuchs, and M. C. Souroujon Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis J. Immunol., May 1, 2005; 174(9): 5324 - 5331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Baggi, A. Annoni, F. Ubiali, M. Milani, R. Longhi, W. Scaioli, F. Cornelio, R. Mantegazza, and C. Antozzi Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor {alpha}-Subunit Induces Experimental Myasthenia Gravis in Rats J. Immunol., February 15, 2004; 172(4): 2697 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-B. Wang, F.-D. Shi, H. Li, B. J. Chambers, H. Link, and H.-G. Ljunggren Anti-CTLA-4 Antibody Treatment Triggers Determinant Spreading and Enhances Murine Myasthenia Gravis J. Immunol., May 15, 2001; 166(10): 6430 - 6436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Barchan, M. C. Souroujon, S.-H. Im, C. Antozzi, and S. Fuchs Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha -subunit PNAS, July 6, 1999; 96(14): 8086 - 8091. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
